H-丝氨酰(TBU)-OTBU | 48067-24-9

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: H-丝氨酰(TBU)-OTBU
• 中文别名: H-丝氨酰(TBU)-OTBU(盐酸盐)；H-SER(TBU)-OTBU、H-丝氨酰(TBU)-OTBU
• 英文名称: O-tert-butyl L-serine tert-butyl ester
• 英文别名: H-Ser(tBu)-OtBu；L-Ser(t-Bu)-Ot-Bu；H-Ser(Bu^t)-OBu^t；H-L-Ser(tBu)-OtBu；tert-butyl O-(tert-butyl)-L-serinate；O-tert-Butyl-L-serin-tert-butylester；O-tert-butylserine tert-butyl ester；Ser(t-Bu)-O-t-Bu；Ser(OtBu)2；(S)-tert-Butyl 2-amino-3-(tert-butoxy)propanoate；tert-butyl (2S)-2-amino-3-[(2-methylpropan-2-yl)oxy]propanoate
• CAS: 48067-24-9
• 化学式: C₁₁H₂₃NO₃
• 分子量: 217.309
• InChiKey: BCCSSBZYBJTLHZ-QMMMGPOBSA-N

物化性质

• 沸点：
  70-71 °C(Press: 0.9 Torr)
• 密度：
  0.969±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  如果按照规定使用和储存，则不会分解，也没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  请将贮藏器保持密封，并存放在阴凉干燥处。确保工作环境有良好的通风或排气设施。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: H-Ser(tbu)-otbu
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: H-Ser(tbu)-otbu
CAS number: 48067-24-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H23NO3
Molecular weight: 217.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  H-丝氨酰(TBU)-OTBU 在 palladium 10% on activated carbon 、 氢气 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 N,N-二异丙基乙胺 、 potassium iodide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Synthesis and antibacterial activity of conjugates between norfloxacin and analogues of the siderophore vanchrobactin

  摘要：

  From synthetic functionalized analogues of vanchrobactin, a siderophore produced by the fish pathogenic bacteria Vibrio anguillarum serotype O2, several vanchrobactin analogues-norfloxacin conjugates were obtained and their antimicrobial activities against the wild-type and mutant strains of Vibrio anguillarum serotype O2 have been determined. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.028
• 作为产物：
  描述：

  O-tert-butyl-L-serine tert-butyl ester hydrochloride 在 Amberlyst A₂₁ 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 H-丝氨酰(TBU)-OTBU
  参考文献：
  名称：

  硅环二肽的合成：二肽 N 端和 C 端的肽延伸

  摘要：

  描述了一种利用硅环氨基酸或肽形成的新型肽键。该工作具有以下优点： (1) 咪唑基硅烷是一种极具吸引力的偶联剂，可用于从 N-、C-末端未保护的氨基酸与氨基酸叔丁酯合成二肽；(2)叔的去保护C末端的-丁酯和环化根据反应条件依次进行，得到新的硅环二肽；(3)环化产物显示出作为肽延伸底物的显着能力，因为硅环化合物可以作为亲核试剂和亲电子试剂，并且这种能力导致一锅位点选择性四肽和寡肽合成。这些创新优势将有助于显着简化经典肽合成。

  DOI：

  10.1021/jacs.1c11260

文献信息

• [EN] DIPHENYLAZETIDINONE DERIVATES PROCESSING CHOLESTEROL ABSORPTION INHIBITORY ACTIVITY<br/>[FR] DERIVES DIPHENYLAZETIDINONE PRESENTANT UNE ACTIVITE D'INHIBITION D'ABSORPTION DU CHOLESTEROL
  申请人：ASTRAZENECA AB

  公开号：WO2005061451A1

  公开（公告）日：2005-07-07

  Compounds of formula (XV): [Chemical formula should be inserted here. Please see paper copy] (XV) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

  公式（XV）的化合物：[应在此处插入化学公式。请参见纸质副本]（XV）（其中变量组如内部定义）药物可接受的盐、溶剂化物、这些盐的溶剂化物和前药及其用作治疗高脂血症的胆固醇吸收抑制剂。还描述了它们的制造过程和含有它们的药物组合物。
• Design and synthesis of chromogenic thiopeptolide substrates as MetAPs active site probes
  作者：Yong-Mei Cui、Jing-Ya Li、Ling-Ling Chen、Jia Li、Qi-Zhuang Ye、Fa-Jun Nan

  DOI：10.1016/j.bmc.2004.03.044

  日期：2004.6

  Twenty one chromogenic thiopeptolide substrates were designed and synthesized as the active site probes and analyzed with each S1 site of mutant residues and enzymes of wild-type MetAP1s. The preliminary enzymatic experiments indicate that cysteine 70 or 202, at either Escherichia coli or human MetAP1, played a crucial role in the methionine hydrolysis.

  设计并合成了二十一种生色硫代peptolide底物作为活性位点探针，并用突变型残基的每个S1位点和野生型MetAP1s的酶进行了分析。初步的酶促实验表明，大肠杆菌或人MetAP1上的半胱氨酸70或202在蛋氨酸水解中起着至关重要的作用。
• Substrate-Directed Lewis-Acid Catalysis for Peptide Synthesis
  作者：Wataru Muramatsu、Tomohiro Hattori、Hisashi Yamamoto

  DOI：10.1021/jacs.9b03850

  日期：2019.8.7

  A Lewis-acid-catalyzed method for the substrate-directed formation of peptide bonds has been developed, and this powerful approach is utilized for the new "remote" activation of carboxyl groups under solvent-free conditions. The presented method has the following advantages: 1) the high-yielding peptide synthesis uses a tantalum catalyst for any amino acids; 2) the reaction proceeds without any racemization;

  一种路易斯酸催化的底物定向形成肽键的方法已经被开发出来，这种强大的方法被用于在无溶剂条件下对羧基进行新的“远程”活化。该方法具有以下优点：1）高产肽合成对任何氨基酸均使用钽催化剂；2) 反应进行时没有任何外消旋化；3）采用钛催化剂的新型底物导向化学连接适用于会聚肽合成。这些优势克服了经典肽合成中一些未解决的问题。
• Synthesis of analogues of ochratoxin A
  作者：Pierluigi Plastina、Alessia Fazio、Mohamed Attya、Giovanni Sindona、Bartolo Gabriele

  DOI：10.1080/14786419.2011.613385

  日期：2012.10

  Four analogues of ochratoxin A (OTA) differing for the aminoacidic moiety were synthesised using ochratoxin α (OTα) as the starting material. The condensation reaction between protected amino acids and OTα, carried out in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC • HCl) and N-hydroxybenzotriazole (HOBt) as coupling agents, followed by deprotection and PTLC purification

  赭曲霉毒素A（OTA）的四个不同的类似物为aminoacidic部分使用赭曲霉毒素合成α（OT α）作为起始材料。保护的氨基酸和OT之间的缩合反应α，在1-乙基-3-（3-二甲基氨基丙基）碳二亚胺盐酸盐（EDC•HCl）中和的存在下进行Ñ羟基苯并三唑（HOBt）作为偶联剂，接着脱保护和PTLC纯化得到OTA丙氨酸，亮氨酸，丝氨酸和在令人满意的产率色氨酸类似物（33-47％，基于OT α）。
• [EN] 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS<br/>[FR] 4-ARYL-2-ANILINO-PYRIMIDINES COMME INHIBITEURS DE PLK KINASES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009112439A1

  公开（公告）日：2009-09-17

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.

  本发明涉及式(Ia)或(Ib)的化合物，其N-氧化物形式，药学上可接受的加盐物，季铵盐，立体异构体，互变异构体，消旋体，代谢物，前药，水合物或其溶剂化合物，其中Y1，m，n，R1；X1；X2；R2；X3；X4；R3；和R4在权利要求中定义的含义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在治疗中的用途。该发明特别涉及激酶抑制剂，用于治疗由激酶介导的疾病状态，特别是PLK4，特别是对治疗涉及异常细胞增殖的病理过程有用的化合物，如肿瘤生长、类风湿关节炎、再狭窄和动脉粥样硬化。